Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine1Financial support for the present study was provided by the Institut Pasteur Fondation and SmithKline Beecham Biologicals. All animal studies were conducted in accordance with the French and Belgian national legislative guidelines for animal experimentation.1

This publication has 21 references indexed in Scilit:

• A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine
  Pediatrics, 1998
• Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
  The Lancet, 1997
• Efficacy of a two-component acellular pertussis vaccine in infants
  The Pediatric Infectious Disease Journal, 1997
• A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
  Vaccine, 1997
• A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine
  New England Journal of Medicine, 1996
• A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
  New England Journal of Medicine, 1996
• Efficacy of acellular pertussis vaccine in early childhood after household exposure
  Published by American Medical Association (AMA) ,1996
• Genetic Relatedness of Bordetella Species as Determined by Macrorestriction Digests Resolved by Pulsed-Field Gel Electrophoresis
  International Journal of Systematic and Evolutionary Microbiology, 1993
• A comparison of the DNA fragment patterns of the mouse-virulent challenge strains and clinical isolates of Bordetella pertussis
  Journal of Infection, 1993
• Reflections on the Efficacy of Pertussis Vaccines
  Clinical Infectious Diseases, 1987